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Introduction
The issue of antibiotic resistance in bacteria is growing. For example, methicillin-resistant Staphylococcus 
aureus (MRSA) is a leading human pathogen. New strains of MRSA are resistant to methicillin and numerous 
other antibiotics, placing the patient in signifi cant danger. Indeed, the Centers for Disease Control revealed in 
2007 that the number of deaths due to MRSA exceeded that of AIDS in the United States. It is no wonder that 
antibiotic resistance is one of the most signifi cant and important health care issues. The ability of bacterial 
pathogens to evade traditional antibiotics is faster than the drug makers’ ability to make new types of clinical 
drugs.1
Evolutionary biologists have seized upon this rapid phenotypic change as alleged powerful evidence for 
Darwinian evolution. Thus, antibiotic resistance is an important two-fold issue involving empirical medical 
science and the volatile origins issue. It is frequently cited as a fact of evolution. Most recently, Carl Zimmer, 
in his new book, Microcosm: E. coli and the New Science of Life, uses drug resistance in Escherichia coli to 
bolster his arguments for macroevolution (or molecules-to-man evolution). One of his chapters, “Darwin at the 
Drugstore,” states that scientists are investigating drug resistance in E. coli to demonstrate their ability to 
undergo “rapid bursts of evolution”.2 Many biologists argue a case for Darwinian medicine—using evolutionary 
explanations to describe the wide variation in antibiotic resistance and adaption to new drugs.
Antibiotic resistance is certainly an example of change, but it is hardly a fact of macroevolution (bacteria 
remain bacteria). Creation microbiologist, Dr. Kevin Anderson, states that such variation in bacteria is 
benefi cial for their survival outcome in a clinical environment, but not a benefi cial mutation. Anderson goes on 
to demonstrate how some “fi tness” cost is often associated with mutations, although reversion mutations may 
eventually recover most, if not all, of this cost for some bacteria.3 A biological cost does occur in the loss of pre-
existing cellular systems or functions. Such loss of cellular activity cannot legitimately be offered as a genetic 
means of demonstrating macroevolution.
Creation biologists have long been interested in discussing antibiotic resistance but have frequently cited 
other scientists’ data to make generalizations about drug-resistant bacteria being less fi t overall than wild-type 
bacteria.4 Although this principle is theoretically simple to state on paper, experiments demonstrating fi tness 
costs have been quite tricky in practice. In some cases, creation biologists have interpreted the data well; in 
other cases they have made wide, sweeping generalizations without data to back up their assertions.
Purpose of Study
In an on-going study at Liberty University, antibiotic resistance in the common red bacteria, Serratia 
marcescens, is being investigated to evaluate biological cost to bacteria due to resistance. The major objective 
of these experiments was to test the hypothesis that ampicillin-resistant bacteria are less “fi t” than their wild-
type counterparts. The investigation focused on the most common clinical, ampicillin-resistant S. marcescens 
strains (WFR) and compared with a wild-type strain. We evaluated the infl uence of ampicillin resistance on the 
bacteria’s overall fi tness in a non-clinical environment.
Serratia marcescens is a Gram-negative, rod-shaped, facultative anaerobe (fi g. 1), is ubiquitous in soil and 
water, and therefore is a common contaminant of food. It is easily grown in the lab and may serve as an ideal 
model for competition studies because of the natural color variation of S. marcescens.5 In the wild, S. marcescens 
is noted for the production of a bright red pigment called prodigiosin.6 In contrast, 95% of clinical, resistant 
strains of Serratia are white or have little pigment.7
S. marcescens is also a common cause of nosocomial (hospital) infections of the digestive and urinary tracts.8
In fact, 92% of all S. marcescens pathogens isolated from clinical settings have acquired ampicillin resistance.9 
The WF strain of Serratia marcescens was fi rst isolated at the Texas Medical Center and has continued in the 
laboratory of Robert Williams for decades. This strain 
was chosen because it has characteristics like the vast 
majority of clinical strains (113/114 strains examined 
by Ding and Williams).10
In our study, we compared the biological fitness of 
Serratia marcescens strains that are red, ampicillin-
sensitive (AMPS) versus white, ampicillin resistant 
(AMPR). We wanted to ascertain whether antibiotic 
resistant mutants are less fit than wild-type. Fitness 
was defined by growth rate and colony “robustness” in 
minimal media.
Minimal Media Simulates Famine Conditions
Initially, it was difficult to demonstrate differences 
between wild-type and clinical strains in a rich media 
(Nutrient or Typticase-soy agar). There were no 
differences in growth rate or colony size. However, after 
switching to minimal media and observing hourly, the 
differences were readily observed. In order to confirm and extend the differences in growth rates between the 
sensitive BS303S strain (isolated from pond water) and the resistant WFR strain, a fitness/competition assay was 
performed. This assay sought to simulate famine conditions in the natural environment by utilizing minimal 
media and to evaluate the wild-type against ampicillin resistant, clinical strains exhibiting loss of prodigiosin 
production. Once subjected to conditions that were “harsh,” differences were seen in their performance (growth 
rate and robustness of colonies).
The Results Show a Difference
One analogy to explain the need to use minimal media in competition studies is the way in which weeds, not 
lush grass, grow during times of heat and drought. Like most people, we like a green lawn filled with robust, 
cultivated grass. During the spring when temperatures are moderate and plenty of rain comes, green grass 
grows well, along with a few weeds. However, during the summer, the maintenance of a good lawn is difficult: 
after a month of “drought,” clover and dandelions take over. The cultivated, green grass corresponds to antibiotic-
resistant bacteria that have grown in the laboratory or (hospital-like environments), and the weeds represent the 
wild-type bacteria. In the spring, cultivated grasses, clover, and dandelions all grow nicely together producing 
a good lawn. When nutrients and proper temperature are maintained, both wild-type and resistant bacteria 
grow nicely in the Petri dish and in the body. But as conditions turn harsh, only the more fit bacteria (wild-
type) grow well. Therefore, in order to simulate competition in the wild, bacteria must be grown on minimal 
media. Minimal media mimics better 
what bacteria experience in a natural 
environment over a period of time. This is 
the place where fitness can be accurately 
assessed. Given a rich media, they grow 
about the same (data not shown).
Sensitive and resistant S. marcescens 
show differences in growth rate. The 
greatest apparent differences observed were 
at 4 and 6 hours (fig. 2). When comparisons 
were made between wild-type and mutant 
strains at other times, differences in growth 
rate were not measurably different. The 
experiments suggest ampicillin resistance 
has a metabolic cost to the S. marcescens 
strains. At least in minimal media, this 
claim is true.
The largest differences in growth rates 
among Serratia strains (BS303S and WFR) 
were observed between 4 and 6 hours (fig. 
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Fig. 1. Phenotypic variation in Serratia marcescens can 
vary among red, pink, white, and other colors
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Fig. 2. Comparisons of WFR (white, ampicillin-resistant) vs. BS 303 
(red, wild-type). Note differences at 4 and 6 hours.
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2). BS303S after four hours had 51% and after six hours had 35% more growth than WFR. As incubation 
time increased, WFR caught up to BS303S, in terms of cell numbers. At the end of 10 hours post inoculation, 
there was only a 4% difference between BS303S and WFR. The wild-type BS303S also had larger colonies 
(data not shown). Thus, slower growth rates observed in the ampicillin-resistant, clinical strains compared to 
the ampicillin-sensitive, wild-type strains, demonstrate that due to this mutation, the bacteria experienced a 
decrease in net cellular function.
These results demonstrate that wild-type BS303S has a significant fitness advantage over the mutant strains 
due to its growth rate and colony size. Therefore, it can be argued that ampicillin resistance mutations reduce 
the growth rate and therefore the general biological fitness of S. marcescens. This study concurs with Anderson 
that while mutations providing antibiotic resistance may be beneficial in certain, specific environments, they 
often come at the expense of pre-existing function, and thus do not provide a mechanism for macroevolution.11
It should be noted that we have found similar results with another Serratia marcescens clinical strain (933) 
and have observed it in E. coli. These findings will be reported in future papers. Our experience with competition 
studies reveals that demonstrating fitness costs in the laboratory is tricky and creation biologists should be 
careful about making dogmatic statements like, “Wild-type bacteria always outcompete antibiotic resistant 
mutants in nature.” Some bacteria that have an antibiotic resistance gene integrated into their chromosome 
can make compensatory mutations, over multiple, successive generations. These resistant bacteria compete 
favorably with wild-type bacteria in nature given certain environmental conditions.12, 13
Conclusions
Darwinian evolutionists attempt to offer explanations on antibiotic resistance and prescriptions for future drug 
development. If they simply suggest an awareness of on-going changes in pathogenic bacteria, we would concur. 
Bacteria do acquire resistance quickly, and many older drugs no longer work in hospitals and clinics. Creation 
microbiologists are interested in finding new drugs that will work and seek to heal the sick (Luke 10:9).
If evolutionists mean that one type of bacteria will “evolve” into another type, we would disagree based 
upon the evidence. A conclusion of these experiments is that acquiring antibiotic resistance through mutation 
or horizontal transfer is “costly.” There is a tradeoff: for survival in a clinical environment (that is, antibiotics 
prevalent), there is a metabolic cost in terms of slower growth. This is called antagonistic pleiotropy. Antagonistic 
pleiotropy refers to the genetic expression of multiple competing effects, some beneficial, but others harmful to 
the organism. It often involves a case where reproduction and viability counter each other in biological fitness.14 
The gene provides a benefit in one circumstance, but has cost in another.
The results of various experiments do show that bacteria can change quickly. Although the acquisition of 
antibiotic resistance does not demonstrate Darwinian evolution, it does demonstrate that bacteria were endowed 
by their Creator to change and adapt very quickly in an almost constantly changing environment. Bacteria 
have tremendous variability, yet there are limits to such change: the continuity, stability, and reliability of such 
bacteria are well known.
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